RhumbLine Advisers’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

RhumbLine Advisers’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-57,190	Closed	-$518K	–	3002
2013 Q4	$518K	Sell	57,190 -200	-0.3%	-$1.44K	﹤0.01%	2235
2013 Q3	$362K	Sell	57,390 -578	-1%	-$3.67K	﹤0.01%	2411
2013 Q2	$395K	Buy	+57,968	New	+$404K	﹤0.01%	2435

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RhumbLine Advisers's CADX Position: Q1 2014 in Review

RhumbLine Advisers sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 57,190 shares — an estimated $518K sold.

RhumbLine Advisers first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $518K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

RhumbLine Advisers reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
RhumbLine Advisers sold 57,190 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $518K.
RhumbLine Advisers first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
RhumbLine Advisers's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $518K in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on RhumbLine Advisers's 13F filing for Q1 2014, filed 6 May 2014.